HemoPill® acute: multicentric retrospective study shows promising results in clinical rou...

The use of the HemoPill acute demonstrated its ability to reliably detect or exclude bleeding

FTRD®: A multicenter retrospective analysis evaluated the risk of appendicitis after EFTR...

A multicenter retrospective analysis of 50 patients undergoing EFTR for colonic lesions involving the appendiceal

HemoPill® acute shows promising results in a non-fasting patient with a mid-gastrointesti...

Ovesco’s first wireless sensor capsule for detection of upper and middle gastrointestinal (GI) bleeding was

Symposiumsreport DGE-BV 2021 – Teil 3
HemoPill® & OTSC®: telemetrische Blutun...

Vorläufige Ergebnisse von RCT Studie zeigen, dass die OTSC First-Line Therapie der Standardtherapie bei akuter

Symposiumsreport DGE-BV 2021 – Teil 2
HemoPill® & OTSC®: telemetrische Blutun...

OTSC® wird in aktuellen Leitlinien für die first-line Versorgung von großen Ulcera und die Therapie

Symposiumsreport DGE-BV 2021 – Teil 1
HemoPill® & OTSC®: telemetrische Blutun...

Der 50. Kongresses der Deutschen Gesellschaft für Endoskopie und bildgebende Verfahren e.V. (DGE-BV) fand vom

FTRD® Closing the gap – Live Webinar am 23. April 2021

Ovesco lädt Sie herzlich ein zu einem Livestream-Webinar über die endoskopische Vollwandresektion mit FTRD® In

FTRD®: international study shows favorable safety profile and efficacy of EFTR in the upp...

FTRD application in 56 patients with lesions in the upper GI tract showed a technical

OTSC®: Systematic review of 3025 patients demonstrates efficacy in GI hemorrhage, perfora...

A systematic review of studies with at least five patients examinating OTSC application for any

Ovesco HemoPill® acute was presented at the International Endoscopy Symposium

HemoPill® acute for gastrointestinal diagnosis and its future clinical routine – an Interview (Click here